Effective Phaco Time and Endothelial Cell Loss When Using Veritas
Part of paid clinical trials in ‘Aiea, Hawaii.
- Sponsor
- Aloha Vision Consultants
- Study ID
- NCT07176416
- Status
- Recruiting
Conditions
- Cataract
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Veritas Vision System — DEVICEVeritas Vision System
Study Details
This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.
Key Dates
- Start date
- Oct 3, 2025
- Status verified
- Oct 2025
- Primary completion
- Oct 1, 2026
- Completion
- Oct 1, 2026
Study Design
- Enrollment
- 50 participants (estimated)
Primary Outcome Measure
Effective phaco time per phacoemulsification procedure [ Time Frame: Surgery (Day 0) ]
Central Contacts
- Alana K Dunn808-688-6898
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Aloha Vision Consultants | ‘Aiea | Hawaii | 96701 | Carlton Yuen, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in ‘Aiea, HI
By research site
Related Studies
- Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence TomographyRecruiting · Oregon Health and Science University · Portland, Oregon
- Intraoperative OCT Guidance of Intraocular Surgery IIRecruiting · Duke University · Durham, North Carolina
- Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital PopulationPHASE4 · Recruiting · University of California, San Francisco · San Francisco, California
- Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood CataractPHASE4 · Recruiting · EyePoint Pharmaceuticals, Inc. · Huntington Beach, California